商品信息
联系客服
郑重提醒：
无质量问题不接受退换货，下单前请仔细核对信息。
下单后请及时联系客服核对商品价格，订单生效后再付款。
PLT VASP/P2Y12
Retour à la liste
| Référence | 7014 |
|---|---|
| Statut | CE |
| Echantillon | 30 µl de sang total citraté |
| Quantité | 10 tests |
| Détection | Fluorescence |
| Application | Pour le suivi des antagonistes spécifiques du récepteur plaquettaire à l’ADP (P2Y12) |
| Composition | - Diluant.- PGE1- PGE1 +ADP - Fixateur- Anticorps monoclonal anti VASP-P- Contrôle isotypique négatif- Réactif de révélation-FITC + contre-marqueur plaquettaire (CD61-PE). |
L"échantillon sanguin est incubé parallèlement en présence de PGE1 seule ou de PGE1+ ADP. Aprés une perméabilisation cellulaire, la molécule VASP sous forme phosphorylée est marquée en immunofluorescence indirecte sans lavage par un anticorps monoclonal spécifique. L"analyse en cytométrie en flux , en double couleur , permet de comparer les deux conditions testées et d"évaluer, pour l"échantillon analysé, la capacité de l"ADP à inhiber cette phosphorylation.
| Date | Nom du document | Taille du fichier | Télécharger |
|---|---|---|---|
| 01/03/2015 | package insert PLT VASP P2Y12 | -478.72 Ko | Télécharger |
| 08/06/2010 | Flyer PLT VASP P2Y12 | -592.82 Ko | Télécharger |
| 01/03/2018 | package insert PLT VASP P2Y12 | -530.45 Ko | Télécharger |
| Auteur | Titre | Année d"édition | Revue |
|---|---|---|---|
| Bagoly Z. et al | How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy? | 2016 | Platelets |
| Danese E. et al | Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry | 2016 | J Thromb Haemost. |
| Storey R.F. et al | Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial | 2016 | J Am Coll Cardiol |
| Rollini F. et al | Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors | 2016 | Thromb Haemost |
| Umemura K et al | Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects | 2016 | Drug Metab Pharmacokinet |
| Franchi F. et al | Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study | 2016 | Circulation |
| Umemura K et al | Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects | 2016 | Drug Metab Pharmacokinet |
| Tang N et al. | The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese | 2015 | Scand J Clin Lab Invest |
| Siller-Matula J. M. et al | How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer? | 2015 | Thromb Haemost |
| Aradi D. et al | Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention | 2015 | Eur Heart J |
| Danese E. et al | Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry | 2015 | J Thromb Haemost |
| Bonello L. et al | Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective study | 2015 | Int J Cardiol |
| Aradi D et al | Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention | 2014 | Eur Heart J. |
| Laine M et al | Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome | 2014 | Thromb Haemost |
| Darlington A et al | Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery | 2014 | Thromb Haemost |
| Patel Y.M. et al | A novel mutation in the P2Y12receptor and a function-reducing polymorphism in PAR-1 in a patient with chronic bleeding | 2014 | J Thromb Haemost |
| Samoš M et al | Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis | 2014 | Am J Emerg Med |
| Wisman P.P et al | Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and | 2014 | J Thromb Haemost |
| Lhermusier T et al | Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. | 2014 | J Interv Cardiol. |
| Jakubowski JA et al | The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study. | 2014 | Thromb Res. |
| Timur AA, et al | Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy | 2014 | Thromb Res. |
| Grosdidier C et al. | Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications | 2013 | Am J Cardiol. |
| Gremmel T et al. | Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation | 2013 | Transl Res. |
| Frelinger A.L et al. | Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet F | 2013 | J Am Coll Cardiol |
| Gaglia MA et al. | Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity | 2013 | Cardiovasc Revasc Med. |
| Wun T et al. | A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease | 2013 | J Hematol Oncol. |
| Delavenne X et al. | Investigation of drug–drug interactions between clopidogrel and fluoxetine | 2013 | Fundam. Clin. Pharmacol. |
| Kerneis M et al. | Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel | 2013 | J Am Coll Cardiol Intv |
| Ferreiro JL et al. | Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy | 2013 | J Am Coll Cardiol |
| Mazur P. et al | Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral arterial disease | 2013 | Platelets |
| Nakata T et al | Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation | 2013 | Circ. J |
| Erlinge D. et al. | Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains noninferiority | 2013 | J Am Coll Cardiol |
| Laine M. et al. | Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention | 2013 | Thromb Res. |
| Kim I.S. et al. | Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in | 2013 | Am Heart J |
| El-Halabi MM et al. | CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Anti-Platelet Action of Clopidogrel | 2013 | J Cardiovasc Pharmacol. |
| Fontana P et al. | Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping | 2013 | J Am Heart Assoc. |
| Gurbel PA et al. | The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study | 2013 | J Am Coll Cardiol. |
| Gremmel T et al. | Response to antiplatelet therapy is independent of endogenous thrombin generation potential | 2013 | Thromb Res. |
| Tello-Montoliu M. et al. | Impact of aspirin dose on adenosine diphosphate-mediated platelet activity Results of an in vitro pilot investigation | 2013 | Thromb Haemost |
| Bonello L. et al. | A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity | 2013 | Int J Cardiol. |
| Cuisset T. et al | Clinical Implications of Very Low On-Treatment Platelet Reactivity in PatientsTreated With Thienopyridine | 2013 | J Am Coll Cardiol |
| Saucedo JF. et al | Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching | 2013 | Thromb Haemost |
| Tantry U.S. | Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding | 2013 | J Am Coll Cardiol. |
| Wang X.D et al. | Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance | 2012 | Eur J Int Med |
| Kobsar A et al. | The thrombin inhibitors, hirudin und Refludan®, activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets | 2012 | Thromb Haemost. |
| Jeong YH. et al. | High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cutoff of VASP-P platelet reactivity index too low?" | 2012 | J Thromb Haemost |
| Frelinger A.L. et al, | A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers | 2012 | J. Am. Coll. Cardiol. |
| Reny J.L. et al. | Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis | 2012 | J Thromb Haemost |
| Tello-Montoliu A.et al. | Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy | 2012 | J. Am. Coll. Cardiol. |
| Ferreiro J.L.et al. | Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus | 2012 | Rev Esp Cardiol. |
| Aradi D et al. | Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity | 2012 | Eur J Clin Invest. |
| Yokoi H et al. | Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention | 2012 | Thromb Res |
| Bonello L. et al | Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel | 2012 | J Thromb Haemost |
| Liang Y et al | Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin | 2012 | J Thromb Thrombolysis |
| BonelloL. et al | Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction | 2012 | Thromb Haemost. |
| Bonello L. et al | Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade | 2012 | Thromb Res |
| Erlinge D. et al | Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients | 2012 | J Am Coll Cardiol |
| Suryadevara S. et al | Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patientswith type 2 diabetes mellitus | 2012 | Thromb Haemost |
| Cuisset T. et al | CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome | 2012 | J Am Coll Cardiol Intv |
| Chang H et al | Modified Diadenosine Tetraphosphates with Dual Specificity for P2Y1 and P2Y12 are Potent Antagonists of ADP-induced Platelet Activation | 2012 | J Thromb Haemost |
| Tello-Montoliu A et al | Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus | 2012 | J Thromb Thrombolysis |
| Morel et al | The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight. | 2012 | Thromb Haemost. |
| Yano H et al | Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin | 2012 | Circ J. |
| KalantziKI et al. | Clopidogrel differentially affects platelet-mediated thrombosis and inflammatoryresponse in patients with acute coronary syndromes | 2011 | J Thromb Haemost. |
| Petrucci G et al. | Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors | 2011 | JPET |
| Morel O et al. | Cardiovascular Mortality in Chronic Kidney Disease Patients UndergoingPercutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel | 2011 | J. Am. Coll. Cardiol. |
| Ueno M et al. | Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease | 2011 | Thromb Haemost |
| Angiolillo DJ et al. | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | 2011 | Thromb Haemost |
| Freynhofer MK et al. | Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for predictionof postprocedural major adverse cardiovascular events | 2011 | Thromb Haemost |
| Mani H. et al. | Platelet function testing in hirudin and BAPA anticoagulated blood | 2011 | Clin Chem Lab Med |
| Szymezak J. et al. | High on-clopidogrel platelet reactivity: Genotyping can help to optimize antiplatelet treatment | 2011 | Thromb Res |
| Pettersen A. et al. | The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel | 2011 | Thrombosis Journal |
| Prüller F. et al. | Low platelet reactivity is recoverd by transfusion ofstored platelets: A healthy volunteer in vivo study | 2011 | J Thromb Haemost |
| Wang XD. et al. | Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance | 2011 | Clin. Cardiol. |
| Frelinger A. et al. | Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications | 2011 | J. Am. Coll. Cardiol. |
| Angiolillo DJ et al. | Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | 2011 | Thromb Haemost. |
| Storey RF et al. | Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses | 2011 | J Thromb Haemost |
| Fontana P et al. | Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study | 2011 | J Thromb Haemost |
| Fernando H et al. | Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel | 2011 | J Thromb Haemost |
| Bonello L et al. | High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes | 2011 | J. Am. Coll. Cardiol. |
| Ferreiro JL et al. | Pharmacodynamic evalutation of pentaprazole therapy on cloppidogrel effect | 2011 | Circ Cardiovasc Interv. |
| Ferreiro JL et al. | Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus | 2011 | Rev Esp Cardiol. |
| Ueno M et al. | Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel | 2011 | J Am Coll Cardiol Intv |
| Bliden KP et al. | The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies | 2011 | Am Heart J. |
| Grdinic A et al. | PCI and clopidogrel: antiplatelet responsiveness and patient characteristics | 2011 | Acta Cardiol. |
| Gaglia MA Jr et al. | Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity | 2011 | Am J Cardiol. |
| Mega J.L et al. | Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease | 2011 | JAMA |
| Tsoumani ME | Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate | 2011 | Angiology |
| MotovskaZ et al. | Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness | 2010 | Int J Cardiol. |
| PalmeriniT. et al, | A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study | 2010 | Thromb Res |
| Bonello L et al. | Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism | 2010 | Int J cardiol. |
| Bonello L et al. | Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients | 2010 | Thromb Res. |
| von Beckerath N et al. | Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry | 2010 | Blood Coagulation and Fibrinolysis |
| Gurbel PA et al. | The Effect of Elinogrel on High Platelet Reactivity During Dual Antiplatelet Therapy and the Relation to CYP 2C19*2 Genotype:First Experience in Patients | 2010 | J Thromb Haemost. |
| Bellemain-Appaix A et al. | Slow Response to Clopidogrel Predicts Low Response | 2010 | J. Am. Coll. Cardiol. |
| Metzmer H et al. | Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring | 2010 | Eur J Anaesthesiol. |
| Cuisset T et al. | Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting | 2010 | Archives of Cardiovascular Disease |
| Gurbel PAet al. | Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study | 2010 | Circulation |
| Small DS et al. | Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial | 2010 | Clin Ther. |
| Flierl U et al. | The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats | 2010 | Thromb Res |
| Bouman HJ et al. | Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel | 2010 | J Thromb Haemost. |
| Gajos G et al. | Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients UndergoingPercutaneous Coronary Intervention | 2010 | J. Am. Coll. Cardiol. |
| El Ghannudi S | Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty | 2010 | J Am Coll Cardiol Intv |
| Bonello L et al. | Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19 2* Loss of Function Polymorphism | 2010 | J. Am. Coll. Cardiol. |
| Delavenne Xet al. | Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests? | 2010 | J Thromb Haemost. |
| Aradi D et al. | Comparison of conventional aggregomerty with VASP for monitoring P2Y12-specifc platelet inhibition | 2010 | Platelets |
| Zighetti ML et al. | Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2y12 receptor for ADP | 2010 | J Thromb Haemost. |
| Bonello L et al. | Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate | 2010 | J. Am Coll Cardiol. |
| Storey RF et al. | Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy | 2010 | J. Am. Coll. Cardiol. |
| Angiolillo DJ et al. | Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study | 2010 | J. Am. Coll. Cardiol. |
| Bonello L et al. | Level of P2Y12-ADP receptor blockade during percutaneous coronary intervention predicts the extent of endothelial injury,assessed by CEC measurement | 2010 | J. Am. Coll. Cardiol. |
| Bjellanda TW et al. | Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest | 2010 | Resuscitation |
| Fu Q et al. | Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in japanese patients undergoing coronary stenting | 2010 | Int Heart J. |
| Fontana P et al. | Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study | 2010 | J Thromb Haemost. |
| Ferreiro JL et al. | Pharmacodynamic effects of concomitant versus stagerred clopidogrel and omeprazole intake | 2010 | Circ Cardiovasc Interv. |
| Tantry U et al. | First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. The ONSET/OFFSET and RESPOND Genotype Studies | 2010 | Circ Cardiovasc Genet. |
| Osmancik P et al. | A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction" | 2010 | Catheter Cardiovasc Interv. |
| Bonello L et al. | Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis | 2009 | Am J Cardiol. |
| Lortie E. et al. | Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits | 2009 | Thromb Res |
| Siller-Matula JM et al. | The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation | 2009 | Thromb Res |
| Bonello L et al. | Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines | 2009 | Heart |
| Hogberg C. et al . | Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment | 2009 | Thrombosis Journal |
| Cuisset T et al. | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response | 2009 | Thromb Res. |
| Varenhorst C et al. | Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease | 2009 | Eur Heart J |
| MotovskaZ et al. | High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial | 2009 | Blood Coagul Fibrinolysis |
| Michelson A. et al | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial | 2009 | European Heart Journal |
| Cuisset T et al. | Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronay syndrome | 2009 | EuroIntervention |
| Aleil B. et al. | CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring | 2009 | J Thromb Haemost |
| Siller-Matula JM et al. | Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel | 2009 | Am Heart J |
| Cuisset T et al. | Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose | 2009 | J. Am. Coll. Cardiol. |
| Alström U et al. | Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery | 2009 | Thromb Res |
| Siller-Matula JM et al. | Cross validation of the Multiple Electrode Aggregometry | 2009 | Thromb Haemost. |
| Gremmel T et al. | Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation | 2009 | Thromb Haemost. |
| James S et al. | Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial | 2009 | Am Heart J |
| Gurbel PA and Tantry U. | Selecting Optimal Antiplatelet Therapy Based on Platelet Function Monitoring in Patients With Coronary Artery Disease | 2009 | Curr Treat Op Cardio Med |
| Frere C et al. | CYP2C19*17 Allele is associated with Better Platelet Response to Clopidogrel in patients admitted for Non-ST Acute Coronary Syndrome | 2009 | J Thromb Haemost. |
| MotovskaZ et al. | Clopidogrel resistance Live" - the risk of stent thrombosis should be evaluated before procedures | 2009 | Thrombosis J |
| MotovskaZ et al. | Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin"s Advantage and the Smoking | 2009 | J Cardiovasc Pharmacol |
| Wallentin L et al. | Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease | 2008 | European Heart Journal |
| Sbrana S et al. | Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation | 2008 | Cytometry Part B |
| Gilard M. et al. | Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study | 2008 | J. Am. Coll. Cardiol. |
| Gurbel PA et al. | Omeprazole A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel | 2008 | J. Am. Coll. Cardiol. |
| Frere C et al. | Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome | 2008 | Am J Cardiol. |
| Angiolillo DJ et al. | Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition onStandard Dose Treatment | 2008 | Am J Cardiol. |
| Bonello L et al. | Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study | 2008 | J. Am. Coll. Cardiol. |
| Jakubowski J et al. | A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry | 2008 | Thromb Haemost. |
| Yano Y et al. | Determinants of thrombin generation,fibrinolytic activity, and endothelial dysfunctionin dual-antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow’s triad | 2008 | Eur Heart J. |
| Umemura K et al, | The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects | 2008 | J Thromb Haemost |
| Bonello L et al, | A threshold of platelet reactivity for ischaemic events? | 2008 | Eur Heart J. |
| Bonello L et al, | Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention | 2008 | Thromb Res |
| Michelson A et al. | P2Y12 Antagonism: Promises and Challenges | 2008 | ATVB |
| Angiolillo DJ et al. | A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study | 2008 | Eur Heart J. |
| Schäfer A et al. | ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay | 2008 | Thromb Haemost |
| Siller-Matula JM et al. | Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel | 2008 | J. Am. Coll. Cardiol. |
| Morel O et al. | Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis? | 2008 | Thromb Haemost |
| Djukanovic N. et al. | Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors | 2008 | J Pharmacol Sci |
| De Miguel A et al. | Clinical implications of clopidogrel resistance | 2008 | Thromb Haemost. |
| WeberAA et al. | Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs | 2008 | Herz |
| Aleil B al. | Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention" | 2008 | J Am Coll Cardiol Intv |
| Erlinge D et al. | Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo | 2008 | J. Am. Coll. Cardiol. |
| Cayla G et al. | Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes | 2008 | Arch Cardiovasc Dis. |
| Aleil B et al. | Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases | 2007 | J Thromb Haemost |
| Angiolilo DJ et al. | Randomized comparison of a high clopidogrel maintenance dose in patients with Diabetis mellitus and coronary artery disease | 2007 | Circulation |
| van Werkum et al. | The flow cytometric VASP assay can be used to determined the effectiveness of clopidogrel in patients treatedwith Abciximab | 2007 | J Thromb Haemost |
| Cuisset T et al. | Lack of association between the 807C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome | 2007 | Thromb Haemost. |
| Mueller Tet al. | Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate® analyzer -comparison with two flow cytometric methods" | 2007 | Thromb Res |
| Cuisset T. et al. | Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome | 2007 | Thromb Res |
| Bonello L et al. | VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events | 2007 | J Thromb Haemost |
| Cattaneo M et al. | Platelet P2 receptors: old and new targets for antithrombotic drugs | 2007 | Cardiovascular Therapy |
| Gurbel PA et al. | Assessment of clopidogrel responsiveness : measurements of maximum platelet agreggation, final platelet agreggation and their correlation with Vasodilator stimulated phosphoprotein in resistant patients | 2007 | Thromb Res |
| Schumacher WA et al. | Biomarker optimization to track antithrombotic and hemostatic effects of clopidogrel | 2007 | J Pharmacol Exp Ther. |
| De Gaetano and Cerletti. | Platelet function, antiplatelet therapy and clinicla outcomes : to test or not to test ? | 2007 | J Thromb Haemost |
| Paniccia R et al. | Different methodologies for evaluating the effect of clopidogrel on platelet function in high isk coronary artery disease patients | 2007 | J Thromb Haemost |
| Dropinski et al. | The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin | 2007 | Thromb Haemost. |
| Fontana P et al. | Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopicogrel responsiveness | 2007 | Thromb Haemost. |
| Morel O et al. | Impaired platelet responsiveness to clopidogrel identified by flow cytometric VASP phosphorylation in patients with subacute stent thrombosis | 2007 | Thromb Haemost. |
| Frere C et al. | ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome | 2007 | Thromb Haemost. |
| Gurbel PA et al. | Platelet function monitoring in patients with coronary artery disease | 2007 | JACC |
| Blindt R et al. | The Significance of Vasodilator-Stimulated Phosphoprotein for Risk Stratification of Stent Thrombosis | 2007 | Thromb Haemost. |
| Eli Lev et al. | Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease | 2007 | Am Heart J |
| Schäfer A et al. | Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ? | 2007 | Thromb Haemost. |
| Wiviott SD et al. | Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention | 2007 | Circulation |
| Montalescot G et al. | A randomized comparison of high clopidogrel loading doses in patients with non -ST-Segment elevation Acute coronary syndromes | 2006 | JACC |
| Gilart M.et al. | Influence of omeprazol on the anti platelet action of clopidogrel associated to aspirin | 2006 | J Thromb Haemost |
| Bura A et al. | Role of the P2Y12 gene polymorphism in the platelet responsiveness to clopidogrel in healty subjects | 2006 | J Thromb Haemost |
| Hulot JS et al. | Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects | 2006 | Blood |
| Cauwenberghs et al. | Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation | 2006 | Transfusion |
| Pampuch et al. | Comparison of VASP phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor | 2006 | Thromb Haemost. |
| Gurbel PA and Tantry U | Drug insight : clopidogrel responsiveness | 2006 | Nat Clin Pract Cardiovasc Med |
| Aleil B et al. | Flow cytometry analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases | 2005 | J Thromb Haemost |
| Aleil B et al. | High stability of blood samples for flowcytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease | 2005 | Thromb Haemost. |
| AleilB and Gachet C | Inter-individual variability in the response to clopidogrel | 2005 | Archives des Maladies du Coeur et des Vaisseaux |
| Gurbel PA et al. | Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis, Results of the CREST Study | 2005 | J Am Coll Cardiol |
| Barragan P et al. | Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilatator-stimulated phosphoprotein phosphorylation | 2003 | Cathet Cardiovasc Intervent |
| Titre | Référence |
|---|---|
| PLATELET GpIIb/IIIa Occupancy | 7001 |
| CY-QUANT VASP/P2Y12 | 7502 |
Retour à la liste
蚂蚁淘电商平台
ebiomall.com
ebiomall.com
公司简介
蚂蚁淘（www.ebiomall.cn）是中国大陆目前唯一的生物医疗科研用品B2B跨境交易平台，
该平台由多位经验丰富的生物人和IT人负责运营。蚂蚁淘B2B模式是指客户有采购意向后在蚂蚁
淘搜索全球供应信息，找到合适的产品后在蚂蚁淘下单，然后蚂蚁淘的海外买手进行跨境采购、
运输到中国口岸，最后由蚂蚁淘国内团队报关运输给客户...
蚂蚁淘承诺
正品保证： 全球直采 在线追溯
蚂蚁淘所有产品都是自运营的，我们已经跟国外多家厂方建立品牌推广合作关系, 获得对方的支持和授权； 同时客户可以通过订单详情查看到货物从厂方至客户的所有流程， 确保货物的来源； 正规报关，提供13%增值税发票。
及时交付： 限时必达 畅选无忧
蚂蚁淘的运营团队都是有着多年经验的成员，他们熟悉海外采购、仓储物流、报关等环节； 同时通过在线的流程监控，蚂蚁淘的进口速度比传统企业提高了50%以上， 部分产品甚至能做到7-10天到货，即蚂蚁淘的“时必达”服务。
轻松采购： 在线下单 简单省事
蚂蚁淘的价格是真实透明的，并且具有很大的价格优势，不需要繁杂的询价比价； 报价单与合同可以直接在线生成或打印；就像在京东购物一样， 您的鼠标点击几 次即完成在蚂蚁淘的采购，订单详情会告诉您所有进程。
售后申请： 耐心讲解 优质服务
蚂蚁淘提供的产品在使用过程中如因产品质量问题有售后需求时， 您可通过我的订单提交您的“申请售后”， 蚂蚁淘产品顾问会第一时间为您处理， 在售后服务过程中如遇到问题也可致电蚂蚁淘客服热线：4000-520-616。
2019-03-05
自动细胞计数仪_CountstarBioLab自动细胞计数仪_德国MMM CountstarBioLab自动细胞计数仪_广州芯康医疗科技有限公司,芯康，医疗，科技，cinkong，广州芯康医疗科技有限公司，广州芯康，深圳芯康，芯康医疗，芯康医疗科技，医用冰箱，超低温冰箱，冰箱，药品保存箱，试剂保存箱，生物安全柜，洗瓶机，玻璃器皿清洗消毒机，口腔器械清洗消毒机，清洗消毒机，牙科清洗消毒机，地巾清洗消毒机，拖布清洗消毒机，手术鞋清洗消毒机，美诺，赛多利斯，MIELE，实验室纯水，tomy，纯水，水机，灭菌锅， 查看更多
>
2019-06-19
Logos Biosystems - Innovative Cellular Imaging Instruments | Logos Biosystems... LUNA-FL™双荧光细胞计数仪 LUNA-FL配备双荧光和明场光学系统,是一个功能强大的... 查看更多
>
2021-08-24
上海吉盛医学科技有限公司在发布的自动细胞计数仪Countstar供应信息，浏览与自动细胞计数仪Countstar相关的产品或在搜索更多与自动细胞计数仪Countstar相关的内容。 查看更多
>
2021-08-17
赛默飞Countess II FL 细胞计数说明书/参数/配置 查看更多
>
2021-09-06
111-035-003jackson二抗|111-035-003现货促销 115-035-003Jackson二抗|115-035-003现货促销 017-000-121Jackson|017-000-121现货促销 24765-1聚乙烯亚胺(PE... 查看更多
>
2019-05-15
伯乐bio-rad货号1450102自动细胞计数仪现货 查看更多
>
2019-09-23
北京达科为生物技术有限公司在发布的一体式细胞计数仪 Cellometer AUTO 1000 Cell Counter供应信息，浏览与一体式细胞计数仪 Cellometer AUTO 1000 Cell Counter相关的产品或在搜索更多与一体式细胞计数仪 Cellometer AUTO 1000 Cell Counter相关的内容。 查看更多
>
2020-05-13
广州安新生物科技有限公司在发布的自动细胞计数仪供应信息，浏览与自动细胞计数仪相关的产品或在搜索更多与自动细胞计数仪相关的内容。 查看更多
>
2019-07-15
乳品体细胞计数仪 查看更多
>
背景：Etirinotecan pegol (EP)为一种独特的拓扑异构酶 1 抑制剂，可促进对 SN38 的持续接触。转移性乳腺癌 (mBC) 患者通过 EP 可获得 29% 的总缓解率，在此基础上又针对 mBC 患者进行了一项全球性临床 III 期 BEACON 试验。借助于患者血样中的循环肿瘤细胞 (CTC) 这一最低侵袭性的方式，可实现对与药物活性相关的药效学(PD) 标记物进行检测。本研究针对在治疗前后分离到的 CTC 建立了多 查看更多
>
2019-08-05
江苏卓微生物科技有限公司在发布的JIMBIO FIL 流式图像细胞计数仪供应信息，浏览与JIMBIO FIL 流式图像细胞计数仪相关的产品或在搜索更多与JIMBIO FIL 流式图像细胞计数仪相关的内容。 查看更多
>
常见问题
蚂蚁淘所售产品均为正品吗？
蚂蚁淘的创始人兼CEO是钟定松先生，具有十年的从业经验，在业界享有良好的口碑；
Ebiomall是跨境直采平台，我们直接从厂家采购，自己的团队负责国际物流和清关，中间没有第三方，蚂蚁淘承诺所售产品仅为正品，假一罚十。
下单后可以修改订单吗？
未确认状态的订单可以修改，打开“订单详情”页面，点击右上角的“修改订单”即可，若已审核确定，则订单无法修改。
商品几天可以发货？
现货产品付款审核后即可发货,大部分期货产品在3周左右即可到货,提供时必达服务的产品订单审核十天内即可发货。
订单如何取消？
如订单处于未确定状态，进入“我的订单"页面，找到要取消的订单，点击“取消订单”按钮。
可以开发票吗？
本网站所售商品都是正规清关，均开具13%正规发票，发票金额含配送费金额，另有说明的除外。
如何联系商家？
蚂蚁淘任何页面都有在线咨询功能，点击“联系客服”、“咨询”或“在线咨询”按钮，均可咨询蚂蚁淘在线客服人员，
或拨打4000-520-616，除此之外客户可在 联系我们页面找到更多的联系方式。
收到的商品少了/发错了怎么办？
同个订单购买多个商品可能会分为一个以上包裹发出，可能不会同时送达，建议查看订单详情是否是部分发货状态；如未收到，可联系在线客服或者致电4000-520-616。
退换货/维修需要多长时间？
一般情况下，退货处理周期为客户收到产品一个月内（以快递公司显示签收时间为准），包装规格、数量、品种不符，外观毁损、短缺或缺陷，请在收到货24小时内申请退换货；特殊商品以合同条款为准。
商品咨询
ProCyte Dx 全自动动物血细胞分析仪 进口 The ProCyte Dx血液...123
鹿衔草2021-07-23
如题，谢谢！
细胞计数仪相关问答,细胞计数仪知道,细胞计数仪疑问,细胞计数...123
独行侠的牵绊2021-07-24
以前用countstar,一块计数板5个孔，后来实验室又换了biorad的TC20，一块板子两个孔，只能计两个数，一盒板子30片500块，价格越来越贵。这样我一个12孔板计个数就要花百来块钱啊。大家都是这么用的？板子是塑料的，有没有什么可以清洗之后重复利用的方法？
流式细胞仪进行干细胞绝对计数的方法123
只死你ayO2017-11-07
取决于你所用机器了。有些型号的机器，可以设置固定体积的计数，这样可以很容易计算细胞浓度从而得出绝对计数。
没有这个功能的机器，必须使用counting beads，也就是在一定体积的血制品样本中加入一定量已知体积的计数微球。这样微球的浓度已知，通过计数1000个微球，得到计数的细胞数量，从而计算出原来样品的细胞浓度。
没有这个功能的机器，必须使用counting beads，也就是在一定体积的血制品样本中加入一定量已知体积的计数微球。这样微球的浓度已知，通过计数1000个微球，得到计数的细胞数量，从而计算出原来样品的细胞浓度。
cd4cd8比值偏低一定是艾滋病吗_家庭医生在线即问即答123
裸色控D02s2021-07-30
免疫细胞（immune cell）是白细胞的俗称，包括淋巴细胞和各种吞噬细胞等，也特指能识别抗原、产生特异性免疫应答的淋巴细胞等，淋巴细胞是免疫系统的基本成分。
淋巴细胞包括 T淋巴细胞（CD3+）、B淋巴细胞（CD3-CD19+）、NK细胞（CD3-CD16+CD56+），其中，T细胞是淋巴细胞的主要组成。
T 淋巴细胞：就是胸腺依赖淋巴细胞（thymus dependent lymphocyte），简称T细胞。
CD3+ 淋巴细胞代表全T淋巴细胞，它包括辅助/诱导T淋巴细胞（CD3+CD4+）、抑制/细胞毒T淋巴细胞（CD3+CD8+）、CD4+T细胞纯真亚群（CD4+CD45RA+/CD4+CD45RA+62L+）和记忆亚群（CD4+CD45RA-/CD4+CD45RO+）、功能亚群（CD28+）、激活亚群（CD38+、HLA-DR+）、凋亡亚群（CD95+）等。
CD4 和 CD4+ 的区别
实际上，病友们常说的CD4就是辅助/诱导T淋巴细胞（CD3+CD4+）。CD4+T淋巴细胞的正确细胞是CD3和CD4全部双阳性的细胞，同样，病友们常说的CD8就是抑制/细胞毒T淋巴细胞（CD3+CD8+）。CD8+T淋巴细胞是CD3和CD8都为阳性的细胞。在识别CD4和CD8中不应包括其他细胞型别的非T淋巴细胞，比如CD3-CD4+细胞，因为此处CD3为阴性。这就是我们经常会看到文字表述CD3、CD4、CD8后面带有+号的原因，或者如同上面一样——出现更让我们这些外行眼晕的CD3+CD4+、CD3+CD8+。
CD3+CD4+ 代表 T辅助/诱导细胞亚群（病友们简称为CD4）
CD3+CD8+ 代表 T抑制/细胞毒性细胞亚群（病友们简称为CD8）
CD3+CD4+/ CD3+CD8+ 代表 T辅助细胞/T抑制细胞的比值 （病友们简称为CD4/CD8比值）
CD4 加 CD8 等于 CD3 吗？
CD3+理论上应约等于CD4+细胞和CD8+细胞的总和，但往往出现CD4+加CD8+细胞之和大于CD3+，这是因为CD4+细胞包括CD3+/CD4+细胞（真正Th细胞）和CD3-CD4+细胞（非Ts细胞），而后者包括CD3-CD8+CD16+56+细胞（一部分NK细胞）和CD3-CD8+CD16+56-（未知细胞），这部分CD8阳性细胞并不表达CD3。真正的TH细胞是CD3+CD4+细胞，真正Ts细胞是CD3+CD8+细胞。尤其当患者NK细胞明显增加时，会使CD4细胞和CD8细胞的总和远大于CD3+细胞。所以，用CD4、CD8的值来得出CD3的值是不准确的，反之亦然。
我们简单记住——CD3约等于但必然小于CD4加CD8之和。
CD4/CD8比值
由于HIV的攻击对象正是人体的CD4细胞，因此CD4记数能够直接反映人体免疫功能，是提供HIV感染患者免疫系统损害状况最明确的指标。CD4细胞的绝对计数通常会随生理情况的不同而有较大的波动，而CD4和CD8的比值则相对比较稳定。HIV/AIDS患者机会性感染发生频率与CD4细胞计数及CD4/CD8比值有着非常密切的关系，CD4 T细胞计数小于200、CD4/CD8比值小于0.20，机会性感染明显增加，且随着病情进展同时发生多种机会性感染的几率也明显增加。
健康人的数值范围
估计鉴于中国地域、种族等差异原因，加之缺少足够的大样本报告，目前E-HIV看到的参考范围各有不同，而且以相对计数（百分比）为主。现在检测外周血中T淋巴细胞及各亚群数量和比例多以流式细胞术进行，流式细胞检测分单平台法和双平台法。单平台法更精确，但标准荧光微球价格昂贵，且流式细胞仪目前操作未实现全程自动化，手工环节误差难以掌握。双平台法用血细胞计数仪测定白细胞计数，再用流式细胞仪检测相对计数（百分比），从而计算出待测细胞的绝对计数，这可能就是我们看到的参考范围多是百分比的缘故。卫生部2011年12月14日发布了《流式细胞术检测外周血淋巴细胞亚群指南》，2012年6月1日正式实施，指南中并未划定健康人的参考数值。诸位可以参看E-HIV此前转载的相关文献：HIV感染者与健康人CD4、CD8及其比值对照和不同年龄组CD4、CD8正常值调查 。或者参看以下不全面的数据：
相对计数参考数据一：
CD3+细胞阳性率61%~85%；CD4+细胞阳性率28%~58%；CD8+细胞阳性率19%~48%；CD4/CD8比值为0.9~2.0。
相对计数参考数据二：
CD3：60-80% ； CD4：35-55% ； CD8：20-30% ；CD4/CD8比值：1.4-2.0。
CD4/CD8比值还有一数据为1.66±0.33
绝对计数：
CD4的正常值范围在不同的国家会有所差别，即便是同一国家的不同地区其指标也可能存在差异，一般比较认可的范围是每微升血中500~1500个。我们实验室通过对我国20—40岁青壮年人群样本的检测发现，CD4的平均值为750个左右，但也不乏每微升血中只含有CD4细胞350或者400个的健康成人。随着年龄增长（如60岁以上），CD4细胞会逐渐减少。单纯的精神因素完全可以导致CD4偏低，如抑郁症可以使CD4低至每微升血300个，甚至200多个。正常情况下CD4/CD8比值介于1.5~2.5之间，95%的正常人CD4/CD8的比值都在1以上，但是也有一些正常人可以发生倒置（即比值低于1）。
aware天 猫可在家自测不用抽血简单方便
—— 以上来自中国疾病预防控制中心性病艾滋病预防控制中心网站上李太生的问答，网址：点击
李太生是卫生部艾滋病临床专家组副组长和卫生部艾滋病专家咨询委员会临床组副组长，所在的北京协和医院是《流式细胞术检测外周血淋巴细胞亚群指南》的主要起草单位。
《流式细胞术检测外周血淋巴细胞亚群指南》中对指标异常的叙述：
CD4+T细胞减少：常见于恶性肿瘤、 遗传性免疫缺陷症、 艾滋病、 应用免疫抑制剂等。
CD8+T细胞：增多见于系统性红斑狼疮、 慢性活动性肝炎、 传染性单核细胞增多症、 恶性肿瘤及其他病毒感染等。降低见于类风湿性关节炎、 糖尿病等。
CD4+T/CD8+T比值：降低见于传染性单核细胞增多症、 急性巨细胞病毒感染、 再生障碍性贫血、 骨髓移植恢复期、 肾病等，艾滋病患者的 CD4/CD8比值多在0.5以下。增高见于移植后发生排异反应、 类风湿性关节炎 、 糖尿病等。
淋巴细胞包括 T淋巴细胞（CD3+）、B淋巴细胞（CD3-CD19+）、NK细胞（CD3-CD16+CD56+），其中，T细胞是淋巴细胞的主要组成。
T 淋巴细胞：就是胸腺依赖淋巴细胞（thymus dependent lymphocyte），简称T细胞。
CD3+ 淋巴细胞代表全T淋巴细胞，它包括辅助/诱导T淋巴细胞（CD3+CD4+）、抑制/细胞毒T淋巴细胞（CD3+CD8+）、CD4+T细胞纯真亚群（CD4+CD45RA+/CD4+CD45RA+62L+）和记忆亚群（CD4+CD45RA-/CD4+CD45RO+）、功能亚群（CD28+）、激活亚群（CD38+、HLA-DR+）、凋亡亚群（CD95+）等。
CD4 和 CD4+ 的区别
实际上，病友们常说的CD4就是辅助/诱导T淋巴细胞（CD3+CD4+）。CD4+T淋巴细胞的正确细胞是CD3和CD4全部双阳性的细胞，同样，病友们常说的CD8就是抑制/细胞毒T淋巴细胞（CD3+CD8+）。CD8+T淋巴细胞是CD3和CD8都为阳性的细胞。在识别CD4和CD8中不应包括其他细胞型别的非T淋巴细胞，比如CD3-CD4+细胞，因为此处CD3为阴性。这就是我们经常会看到文字表述CD3、CD4、CD8后面带有+号的原因，或者如同上面一样——出现更让我们这些外行眼晕的CD3+CD4+、CD3+CD8+。
CD3+CD4+ 代表 T辅助/诱导细胞亚群（病友们简称为CD4）
CD3+CD8+ 代表 T抑制/细胞毒性细胞亚群（病友们简称为CD8）
CD3+CD4+/ CD3+CD8+ 代表 T辅助细胞/T抑制细胞的比值 （病友们简称为CD4/CD8比值）
CD4 加 CD8 等于 CD3 吗？
CD3+理论上应约等于CD4+细胞和CD8+细胞的总和，但往往出现CD4+加CD8+细胞之和大于CD3+，这是因为CD4+细胞包括CD3+/CD4+细胞（真正Th细胞）和CD3-CD4+细胞（非Ts细胞），而后者包括CD3-CD8+CD16+56+细胞（一部分NK细胞）和CD3-CD8+CD16+56-（未知细胞），这部分CD8阳性细胞并不表达CD3。真正的TH细胞是CD3+CD4+细胞，真正Ts细胞是CD3+CD8+细胞。尤其当患者NK细胞明显增加时，会使CD4细胞和CD8细胞的总和远大于CD3+细胞。所以，用CD4、CD8的值来得出CD3的值是不准确的，反之亦然。
我们简单记住——CD3约等于但必然小于CD4加CD8之和。
CD4/CD8比值
由于HIV的攻击对象正是人体的CD4细胞，因此CD4记数能够直接反映人体免疫功能，是提供HIV感染患者免疫系统损害状况最明确的指标。CD4细胞的绝对计数通常会随生理情况的不同而有较大的波动，而CD4和CD8的比值则相对比较稳定。HIV/AIDS患者机会性感染发生频率与CD4细胞计数及CD4/CD8比值有着非常密切的关系，CD4 T细胞计数小于200、CD4/CD8比值小于0.20，机会性感染明显增加，且随着病情进展同时发生多种机会性感染的几率也明显增加。
健康人的数值范围
估计鉴于中国地域、种族等差异原因，加之缺少足够的大样本报告，目前E-HIV看到的参考范围各有不同，而且以相对计数（百分比）为主。现在检测外周血中T淋巴细胞及各亚群数量和比例多以流式细胞术进行，流式细胞检测分单平台法和双平台法。单平台法更精确，但标准荧光微球价格昂贵，且流式细胞仪目前操作未实现全程自动化，手工环节误差难以掌握。双平台法用血细胞计数仪测定白细胞计数，再用流式细胞仪检测相对计数（百分比），从而计算出待测细胞的绝对计数，这可能就是我们看到的参考范围多是百分比的缘故。卫生部2011年12月14日发布了《流式细胞术检测外周血淋巴细胞亚群指南》，2012年6月1日正式实施，指南中并未划定健康人的参考数值。诸位可以参看E-HIV此前转载的相关文献：HIV感染者与健康人CD4、CD8及其比值对照和不同年龄组CD4、CD8正常值调查 。或者参看以下不全面的数据：
相对计数参考数据一：
CD3+细胞阳性率61%~85%；CD4+细胞阳性率28%~58%；CD8+细胞阳性率19%~48%；CD4/CD8比值为0.9~2.0。
相对计数参考数据二：
CD3：60-80% ； CD4：35-55% ； CD8：20-30% ；CD4/CD8比值：1.4-2.0。
CD4/CD8比值还有一数据为1.66±0.33
绝对计数：
CD4的正常值范围在不同的国家会有所差别，即便是同一国家的不同地区其指标也可能存在差异，一般比较认可的范围是每微升血中500~1500个。我们实验室通过对我国20—40岁青壮年人群样本的检测发现，CD4的平均值为750个左右，但也不乏每微升血中只含有CD4细胞350或者400个的健康成人。随着年龄增长（如60岁以上），CD4细胞会逐渐减少。单纯的精神因素完全可以导致CD4偏低，如抑郁症可以使CD4低至每微升血300个，甚至200多个。正常情况下CD4/CD8比值介于1.5~2.5之间，95%的正常人CD4/CD8的比值都在1以上，但是也有一些正常人可以发生倒置（即比值低于1）。
aware天 猫可在家自测不用抽血简单方便
—— 以上来自中国疾病预防控制中心性病艾滋病预防控制中心网站上李太生的问答，网址：点击
李太生是卫生部艾滋病临床专家组副组长和卫生部艾滋病专家咨询委员会临床组副组长，所在的北京协和医院是《流式细胞术检测外周血淋巴细胞亚群指南》的主要起草单位。
《流式细胞术检测外周血淋巴细胞亚群指南》中对指标异常的叙述：
CD4+T细胞减少：常见于恶性肿瘤、 遗传性免疫缺陷症、 艾滋病、 应用免疫抑制剂等。
CD8+T细胞：增多见于系统性红斑狼疮、 慢性活动性肝炎、 传染性单核细胞增多症、 恶性肿瘤及其他病毒感染等。降低见于类风湿性关节炎、 糖尿病等。
CD4+T/CD8+T比值：降低见于传染性单核细胞增多症、 急性巨细胞病毒感染、 再生障碍性贫血、 骨髓移植恢复期、 肾病等，艾滋病患者的 CD4/CD8比值多在0.5以下。增高见于移植后发生排异反应、 类风湿性关节炎 、 糖尿病等。
贝克曼z2全自动细胞分析计数仪详细介绍全自动系统操作简易数据 豆...123
西b宰章82021-08-02
贝克曼细胞分析计数仪采用库尔特原理计数，将细胞计数与细胞直径大小测量功能合二为一，可用于细胞、颗粒计数及粒度分析。
印度制药企业名单_文档之家123
斩风站2021-07-20
各位站友，本人实验小白，现需要做一PCR实验。
需要测量转染之后细胞某mRNA表达变化。
实验组给予转染，空白组做对照。
做PCR的时候肯定是要求两组的细胞计数是一样的，请问是转染之前还是转染之后对两组进行计数呢？如果样品两边计数不一样，怎么让做实验的时候两边细胞数目变成一样呢？
需要测量转染之后细胞某mRNA表达变化。
实验组给予转染，空白组做对照。
做PCR的时候肯定是要求两组的细胞计数是一样的，请问是转染之前还是转染之后对两组进行计数呢？如果样品两边计数不一样，怎么让做实验的时候两边细胞数目变成一样呢？
手持式细胞计数仪是计数活细胞还是死细胞_问答详情_蚂蚁淘,【正品...123
SB沃懒42021-07-29
1,活细胞和死细胞不易分开，数出来的细胞是活的和死的总合
2，细胞溶液必须均匀，再用之前要震荡均匀，否则细胞沉在试管底部，容易出现误差
2，细胞溶液必须均匀，再用之前要震荡均匀，否则细胞沉在试管底部，容易出现误差
细胞计数仪相关问答,细胞计数仪知道,细胞计数仪疑问,细胞计数...123
紫眼影20102021-08-01
有没有使用细胞计数仪的战友，我实验室想购买，能不能提供一些产品的厂家和型号供选择；以及价位。包括进口和国产的，谢谢！
国产全自动血细胞计数仪哪个牌子好机械知道问答买卖机械网123
姿态340I92017-10-03
国产的生产血液分析仪，也就是血细胞分析仪，有那几个厂家，其中那几个厂家生产的血球分析仪好点，请标明厂家和所生产的分析仪牌子问题补充：都不好。
这样的回答可能没分，好和不好都是比较出来的，一群国产的放在一起比总有个性能比较均衡，比较突出性价比好的，
还是没有和说那个厂家的好桂林的呢好像是优利特这个厂家在做，特康的前身呢就是百特，现在的百特呢基本上是在做试剂，这些东西呢。
也搜索的到的，不过答案还是比较接近的，但想知道的是国产那个厂家生产的比较好，而只回答了一半就和介绍了下国产的血球分析仪有那个几个大的厂家，没有和区分那个最好那个第二那个次点，或许一堆鸡蛋里实在挑不出骨头。
具所知呢迈瑞的好点特康实力没有迈瑞好，迈瑞吸引了一批外资在搞研发，桂林的呢好像有个优利特现在出血分析仪，他做的尿分析仪市场的占有还可以，血的反应不是很强烈。
实在是想找个内行的给比较下。
这样的回答可能没分，好和不好都是比较出来的，一群国产的放在一起比总有个性能比较均衡，比较突出性价比好的，
还是没有和说那个厂家的好桂林的呢好像是优利特这个厂家在做，特康的前身呢就是百特，现在的百特呢基本上是在做试剂，这些东西呢。
也搜索的到的，不过答案还是比较接近的，但想知道的是国产那个厂家生产的比较好，而只回答了一半就和介绍了下国产的血球分析仪有那个几个大的厂家，没有和区分那个最好那个第二那个次点，或许一堆鸡蛋里实在挑不出骨头。
具所知呢迈瑞的好点特康实力没有迈瑞好，迈瑞吸引了一批外资在搞研发，桂林的呢好像有个优利特现在出血分析仪，他做的尿分析仪市场的占有还可以，血的反应不是很强烈。
实在是想找个内行的给比较下。
设计引物遵循原则、引物保存和各种PCR的引物设计资讯分析测试...123
zqzsuper2021-08-11
流式细胞仪干细胞计数程序123
窝窝荼蘼丶2582017-10-03
可以的，目前根据机器的型号不同，可以有两种方法。 比较常用的是用计数微球。比如临床上的CD4细胞绝对计数，就是采用这个方法。试管内事先已经有固定数目的计数微球和染色抗体。按要求加入固定体积的抗凝血液，裂解红细胞后上机。
【防火墙技术连载3】强叔侃墙基础知识篇华为防火墙产品一览123
ainidely2017-10-03
为了让更多的客户体验Countstar细胞计数仪带来的高效与便捷，特推出此次优惠活动，只要您在定期内使用Countstar细胞计数板达到规定数量，就免费提供一台Countstar细胞计数仪供您使用。
凡向公司申请者均可获得免费一周的仪器试用机会，您可根据试用效果决定是否申请长期免费使用。申请者需与公司签订使用协议。在免费使用期间，公司会保证仪器持续、稳定的运行。当您累计使用的耗材量达到规定的最低检测量时，仪器可免费赠送！
凡向公司申请者均可获得免费一周的仪器试用机会，您可根据试用效果决定是否申请长期免费使用。申请者需与公司签订使用协议。在免费使用期间，公司会保证仪器持续、稳定的运行。当您累计使用的耗材量达到规定的最低检测量时，仪器可免费赠送！
▍
品牌分类
▍
官网分类
▍
品牌问答
